Business
Profound Medical to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
TORONTO, ON / ACCESSWIRE / November 8, 2018 / Profound Medical Corp. (TSX: PRN; OTCQX: PRFMF...
About this update from Profound Medical Corp
[{"type":"text","content":"\nProfound Medical to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics ForumTORONTO, ON / ACCESSWIRE / November 8, 2018 / Profound Medical Corp. (TSX: PRN; OTCQX: PRFMF) (\"Profound\" or the \"Company\"), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (\"MR\") imaging combined with the safety and ablation power of directional and focused ultrasound technology for the incision-free ablation of diseased tissue, announced today that management will present an update on the Company's business at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018, at 1:00 p.m. Eastern Time at the Westin Grand Central Hotel, New York, NY.The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under \"Webcasts\" in the Investor Relations section.About Profound Medical Corp.The Profound Medical Corp. team is committed to creating the powerful combination of real-time magnetic resonance guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patients and clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to \"profoundly\" change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives.Profound is commercializing a novel technology, TULSA-PRO®, which combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO® is CE marked and Profound is currently conducting a pilot commercial launch of the technology in key European and other CE mark jurisdictions. The Company is also sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which, if successful, is expec...